Hāʻawi pololei ka hale hana i ka 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2

Maʻa mau mākou e noʻonoʻo a hoʻomaʻamaʻa e pili ana i kāu loli o ke kūlana, a ulu aʻe.Manaʻo mākou i ka loaʻa ʻana o ka noʻonoʻo a me ke kino ʻoi aku ka maikaʻi o ke ola no ka Factory E hoʻolako pololei i ka 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, ʻO kā mākou manaʻo e kōkua i nā mea kūʻai aku e ʻike i kā lākou pahuhopu. .Ke hana nei mākou i nā hana maikaʻi e hoʻokō i kēia pilikia lanakila-lanakila a hoʻokipa maikaʻi iā ʻoe e kau inoa pono iā mākou.
Maʻa mau mākou e noʻonoʻo a hoʻomaʻamaʻa e pili ana i kāu loli o ke kūlana, a ulu aʻe.Manaʻo mākou i ka loaʻa ʻana o ka noʻonoʻo a me ke kino ʻoi aku ka maikaʻi me ke ola noKina 4-Dibuthylamino-2-Hydroxybenzophenone a me Bba, ʻO kā mākou loaʻa mau ʻana o nā huahana kiʻekiʻe a me nā hoʻonā i hui pū ʻia me kā mākou lawelawe mua-kūʻai maikaʻi loa a ma hope o ke kūʻai aku e hōʻoia i ka hoʻokūkū ikaika i kahi mākeke ulu honua.hoʻokipa i nā mea kūʻai hou a me nā mea kahiko mai nā ʻano āpau o ke ola e hoʻokaʻaʻike mai iā mākou no nā pilina ʻoihana e hiki mai ana a me ka kūleʻa like!

Hoʻohana ʻia ka 2'-Methoxy-3′-nitro-biphenyl-3-carboxylic acid ma ke ʻano he waena o Eltrombopag.
ʻO Eltrombopag, i hoʻomohala ʻia e GlaxoSmithKline (GSK) ma UK a ma hope i hoʻomohala pū ʻia me Novartis ma Switzerland, ʻo ia ka mea mua a ʻae wale ʻia ka mole liʻiliʻi non peptide TPO receptor agonist ma ka honua.Ua ʻae ʻia ʻo Eltrombopag e ka US FDA ma 2008 no ka mālama ʻana i ka idiopathic thrombocytopenic purpura (ITP), a ma 2014 no ka mālama ʻana i ka anemia aplastic koʻikoʻi (AA).ʻO ia ka lāʻau lapaʻau mua i ʻae ʻia e ka US FDA no ka mālama ʻana iā AA i nā makahiki he 30 i hala iho nei.
Ma December2012, ua apono ka US FDA ia Eltrombopag no ka lapaau ana i ka thrombocytopenia i na ma'i me ka ma'i hepa C (CHC), i hiki i na ma'i hepa C me ka ilihune prognosis ma muli o ka helu platelet ha'aha'a hiki ke ho'omaka a mālama i ka interferon ma muli o ka ma'i ma'i o ka ate.Ma Feberuari 3,2014, ua hoʻolaha ʻo GlaxoSmithKline ua hāʻawi ka FDA i ka hōʻailona lāʻau lapaʻau holomua o Eltrombopag no ka mālama ʻana i ka hemopenia i nā maʻi me ka puke kemika aplastic anemia (SAA) ʻaʻole i pane piha i ka immunotherapy.Ma ʻAukake 24, 2015, ua ʻae ka US FDA iā Eltrombopag no ka mālama ʻana i ka thrombocytopenia i nā pākeke a me nā keiki o 1 makahiki a ʻoi aku me ka thrombocytopenia immune maʻi (ITP) i lawa ʻole ka pane ʻana i nā corticosteroids, immunoglobulins a splenectomy.Ma Ianuali4,2018, ua ʻae ʻia ʻo Eltrombopag e papa inoa ma Kina no ka mālama ʻana i ka thrombocytopenia immune mua (ITP).

Maʻa mau mākou e noʻonoʻo a hoʻomaʻamaʻa e pili ana i kāu loli o ke kūlana, a ulu aʻe.Manaʻo mākou i ka loaʻa ʻana o ka noʻonoʻo a me ke kino ʻoi aku ka maikaʻi o ke ola no ka Factory E hoʻolako pololei i ka 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, ʻO kā mākou manaʻo e kōkua i nā mea kūʻai aku e ʻike i kā lākou pahuhopu. .Ke hana nei mākou i nā hana maikaʻi e hoʻokō i kēia pilikia lanakila-lanakila a hoʻokipa maikaʻi iā ʻoe e kau inoa pono iā mākou.
Hāʻawi pololei ʻo FactoryKina 4-Dibuthylamino-2-Hydroxybenzophenone a me Bba, ʻO kā mākou loaʻa mau ʻana o nā huahana kiʻekiʻe a me nā hoʻonā i hui pū ʻia me kā mākou lawelawe mua-kūʻai maikaʻi loa a ma hope o ke kūʻai aku e hōʻoia i ka hoʻokūkū ikaika i kahi mākeke ulu honua.hoʻokipa i nā mea kūʻai hou a me nā mea kahiko mai nā ʻano āpau o ke ola e hoʻokaʻaʻike mai iā mākou no nā pilina ʻoihana e hiki mai ana a me ka kūleʻa like!